IV Crush Explained: Why DFTX Faded on a 20% Gap
A Phase 3 win, a 20% gap, and an IV crush that ate half of it by the closing bell
Most publishers show you the winners and bury the rest. We post the actual tickets — including the legs that worked against us — so you can judge the method before you ever pay us a dollar.
Get The Free Reports →Psychedelic biotech stocks just had their biggest week of 2026. On August 12, Definium Therapeutics delivered exactly the Phase 3 result the bulls wanted — the stock opened up 20%, then gave back more than half of it before the closing bell. The culprit has a name — IV crush — and if you want to understand why most retail traders lose money on binary events they called correctly, that single day is the entire lesson.
Psychedelic biotech stocks just cleared the sector’s most important hurdle of 2026, and they did it twice in one week. Definium (NASDAQ: DFTX) posted its second straight successful Phase 3 readout. COMPASS Pathways (NASDAQ: CMPS) moved another step closer to becoming the first company to put a psychedelic therapy in front of the FDA for final approval.
Both are bullish developments. Neither one is a reason to buy calls on Monday morning — and IV crush is exactly why. Here’s the read.
What Definium Actually Delivered
The VOYAGE trial tested DT120 ODT — an orally disintegrating tablet formulation of lysergide — in adults with generalized anxiety disorder. It’s the second Phase 3 win for the compound, following the EMERGE study in major depressive disorder back in June. Definium published the full topline release on August 12.
| Metric | Result |
|---|---|
| Primary endpoint | Met — plus all key secondary endpoints |
| HAM-A change at Week 12 | −11.6 points on DT120 vs. −6.2 on placebo |
| Placebo-adjusted effect | −5.4 points (p<0.0001) |
| Onset | Measurable by Day 2, sustained through the blinded period |
| Enrollment | 214 adults, roughly 35 U.S. sites |
| Safety | Adverse events mostly mild to moderate and transient, concentrated on dosing day. No new signals, including none related to suicidality. |
Context matters on that 5.4-point figure. Ahead of the readout, the threshold separating a genuine multi-indication validation from a merely acceptable outcome was roughly five points with clean safety. Definium cleared it. Chief executive Rob Barrow said the results “should raise the bar for what patients and clinicians expect from GAD treatments.”
Two Phase 3 wins across two separate indications gives Definium the broadest late-stage clinical foundation in the sector. The company is carrying roughly $1.1 billion in cash after its June financing, with a runway management believes extends into 2030. That combination — data plus balance sheet — is rare in pre-revenue biotech.
So Why Did The Stock Fade?
Here’s the sequence, and it’s worth walking through slowly.
- Tuesday, August 11: DFTX fell 9% into the print. Its worst single day in nine months. Investors were de-risking ahead of a binary.
- Wednesday premarket: Data drops. Stock jumps roughly 20%.
- Wednesday close: Up about 9%. Roughly half the gap surrendered during the session.
Nothing in the data changed between the open and the close. What changed was implied volatility. This is IV crush, and it is the single most expensive lesson in event trading.
Before a binary catalyst, option premiums inflate because the market is pricing an enormous range of outcomes. The moment the news prints, that uncertainty is gone — and the premium evaporates with it. Traders call it IV crush, and it does not care whether you were right.
A trader who bought August calls into the VOYAGE print could have been completely right about the science and still lost money. The stock went up. Their position didn’t. That is not bad luck. That is IV crush doing exactly what it was always going to do.
The flip side of that same mechanic is where a professional usually wants to be — selling the inflated premium rather than buying it. We did exactly that into Nvidia’s August earnings print, and the full breakdown is here: Nvidia Earnings Options: The Iron Condor That Paid In Full.
Add one more layer: DFTX had already run more than 200% year to date coming into this. When a stock has tripled in anticipation of a result, a good result is priced in. It takes a spectacular result to move it further. This is the definition of a high-expectation setup — high expectations plus IV crush is where undisciplined traders get hurt most often.
The lesson isn’t “don’t trade catalysts.” It’s that once IV crush is in play, how you structure the position matters more than whether you get the direction right.
How To Structure Around IV Crush
Talk is cheap, so here’s the actual ticket. This is the DFTX structure Whiz staged on August 7 — five days before VOYAGE printed, with the stock at $45.14 and nobody yet knowing whether the trial would hit or miss.
Four-leg custom spread staged August 7, 2026 at a $6.80 limit debit — roughly $680 before commissions. A staged order, not a confirmed execution.
Four legs, and each one has a job:
| Leg | What It Does |
|---|---|
| Buy Jan 2028 $45 call Sell Jan 2028 $45 put | Together these two create synthetic long exposure — behaves like roughly 100 shares of DFTX at $45, without tying up the capital to buy them. |
| Buy Jan 2028 $37 put | The floor. This is the leg that converts an unlimited-downside position into a defined-risk one. |
| Sell Aug 2026 $47 call | Sells the expensive near-term volatility into the catalyst and offsets part of the cost of that floor. |
Total cost: roughly $680 to control about $4,500 of stock exposure, with a hard terminal floor beneath it and seventeen months of runway. Compare that to buying August calls into the print and watching IV crush evaporate them overnight. The long-dated legs barely notice the volatility reset; only the short August call is exposed to it, and that one is working for us.
Broker risk/reward snapshot. Note the underlying reads $36.90 here versus $45.14 on the order ticket — the two screens were captured at different moments, so treat these probabilities and P/L figures as a stale model estimate rather than live math. This is exactly why we teach members to re-run risk with synchronized prices before committing size.
That short August $47 call is a real trade-off, not a free lunch. When DFTX gapped on the VOYAGE news, that leg worked against the position and capped near-term upside. That’s the price paid for financing the downside floor, and it was a known cost going in — the same IV crush that punishes call buyers is what made that short call worth selling in the first place.
Once the August call is closed, rolled, or expires, the January 2028 core has uncapped upside again with the floor still underneath it. Which is the whole point: the structure survives the catalyst either way. A right call and a wrong call both leave you in business.
COMPASS: The Slower, Cleaner Path
While Definium owns the near-term clinical drama, COMPASS Pathways owns the regulatory lead — and it’s a different kind of trade entirely.
COMP360, the company’s synthetic psilocybin therapy for treatment-resistant depression, is already inside the FDA. COMPASS is filing its New Drug Application on a rolling basis, meaning the agency reviews modules as they arrive rather than waiting for a complete package. Final submission is targeted for the fourth quarter of 2026, with commercial launch expected in the first half of 2027, per the company’s most recent quarterly update.
The supporting clinical picture:
- Two positive Phase 3 trials, with benefit appearing rapidly and holding through at least six months.
- In the COMP006 study, 39% of patients on the 25mg dose hit a clinically meaningful response at Week 6 and maintained it on average through Week 26.
- Nearly 30% of Week 6 responders reached remission after retreatment.
- Breakthrough Therapy designation from the FDA, plus a National Priority Voucher that may compress review time.
- $433 million in cash at quarter end, funding operations into 2028.
One accounting note that tripped up headline readers on both names: the enormous per-share losses reported in Q2 were driven overwhelmingly by non-cash warrant revaluations, not by operational burn. COMPASS took a $205.6 million fair-value hit. Definium took roughly $86.2 million. Neither figure represents cash leaving the building. If you traded these names off the EPS miss, you traded an accounting artifact.
FDA acceptance of the completed filing. The final approved label. REMS requirements and how much clinical monitoring time gets mandated. Site certification and inspections. And DEA rescheduling — because approval alone doesn’t make a Schedule I substance prescribable.
The priority voucher may accelerate review once the submission is complete. It does not guarantee a compressed approval clock, and the first-half 2027 launch target depends on every one of the items above landing on schedule.
The Catalyst Map From Here
| Timing | Event | Why It Matters |
|---|---|---|
| Sept 2026 | DFTX — PANORAMA Phase 3 GAD readout | Replication. One Phase 3 win is data; two is a franchise. A miss here materially damages the GAD filing package. |
| Q4 2026 | CMPS — final COMP360 NDA submission | The decisive regulatory event. Completes the rolling filing and starts the formal review clock. |
| 2027 | DFTX — ASCEND Phase 3 MDD | Second MDD study required before a credible NDA package can come together. |
| H1 2027 | CMPS — targeted commercial launch | Contingent on FDA approval and DEA rescheduling. Slippage risk is real. |
| Ongoing | Both — label, REMS, payer coverage, scheduling | Determines whether approval translates into an actual commercial business. |
Definium is not close to filing. Before an NDA is realistic the company still needs the second GAD readout, the ASCEND MDD study, sufficient long-term safety data, manufacturing validation, and FDA agreement on the submission and REMS framework. The stock is trading on clinical momentum, not regulatory proximity. Know which one you’re buying.
How We Trade Psychedelic Biotech Stocks
Psychedelic biotech stocks are built on binary catalysts, which makes them the most dangerous terrain in the market for an undisciplined trader. The moves are violent in both directions and the timing is never in your control.
That doesn’t mean you avoid it. It means you never take a position where an adverse outcome can do unlimited damage. Every tactic we place in this sector shares three characteristics:
- Defined terminal risk. Before entry, the worst-case number is known and accepted. No exceptions — and no position is ever actually “safe”, it either has defined risk or it doesn’t.
- Duration that outlasts the catalyst. Long-dated structures don’t get destroyed by a single bad print or a single delayed timeline.
- Premium sold where volatility is expensive. If the market wants to overpay for near-term uncertainty, we’re happy to be on the other side of that — collecting IV crush instead of paying it.
That’s the difference between speculating on psychedelic biotech stocks and taking a professional position in them. Same thesis, same catalyst, same IV crush — completely different outcome distribution.
None of it starts with the trade, either. Every position we take runs top down through Strategic, Operational, Tactical — the world, then the domestic calendar, then the order ticket. Execution is the last step, not the first.
Buy long-dated. IV crush hits front-month premium hardest; a January 2028 contract barely registers the reset. Sell the expensive near-term contract rather than buying it, so the crush pays you. And define the downside before entry so a bad print is survivable rather than terminal.
Do those three things and IV crush stops being the reason your correct call lost money. It becomes something you are positioned to collect.
The Tactics Behind This Trade
Every piece of this position is something we teach:
- Synthetic Stock Strategy — own the stock for a fraction of the capital, with a floor underneath it
- What Are LEAPS? — long-dated contracts, and why time stops fighting you
- What Is An Iron Condor? — the defined-risk way to sell expensive volatility
- Nvidia Earnings Options: The Iron Condor That Paid In Full — IV crush traded from the selling side, on a $5 trillion stock
- Learn Options Trading — free training from a fighter pilot
More closed positions with the tickets attached are in the Trade Alerts archive.
Get The Full Psychedelic Sector Report — Free
The complete institutional breakdown of CMPS, DFTX, ATAI and HELP — the names, the catalyst timelines, the regulatory risk map, and the options tactics we use to take defined-risk positions in a sector this volatile.
Plus two more free reports: AI Supercycle and Bullish on ‘Merica SPX. Hedge fund quality intel usually reserved for high-net-worth clients at Goldman Sachs, JP Morgan and Morgan Stanley.
Get All Three Reports Free →“Trading is a form of combat. There’s a winner and there’s a loser. What side are you on?”
Fight’s On,
Matthew “Whiz” Buckley
CEO, TOPGUN Options | Wall Street Managing Director | TOPGUN Fighter Pilot | President, No Fallen Heroes Foundation | Founder, Sacred Warrior Fellowship
